Cytodyn Inc (CYDY)

[gestalt2]

I do agree with the RS right away, CYDY has not show the ability to increase share price organically. why assume that future trial results and presenting at conferences will raise the stock price? My concern however is that if we vote on no RS extension and the board decides to simply not do it by the Aug '16 deadline then what? what if they do the RS and once on the nasdaq the share price dwindles below $2 and they end up not staying in the nasdaq? i'm concerned about the risks without knowing why the company wants this flexability - timing is everything in these decisions.